"The availability of both one-month and three-month Eligard
provides new alternatives to current prostate cancer therapy," said
David R. Bethune, Atrix's chairman and chief executive officer.
"The Eligard products have attributes and features that may be
beneficial to patients and caregivers alike. We foresee potential
benefits to the physician who wants an effective treatment for the
advanced prostate cancer patient; to the patient who uses this
therapy; and to the nurse who administers the treatment."

The launch of Eligard 22.5mg prostate cancer product coincides
with the start of National Prostate Cancer Awareness Month.
According to the National Cancer Institute, a majority of advanced
prostate cancer patients receive leutenizing hormone releasing
hormone (LHRH) therapy during the course of their treatment.

The American Cancer Society lists prostate cancer as the most
common cancer, excluding skin cancers, in American men. It is
estimated that approximately 189,000 new cases of prostate cancer
will be diagnosed in the United States this year and approximately
30,200 men will die of the disease. Approximately one man in six
will be diagnosed with prostate cancer during his lifetime.

Atrix received approvals from the FDA for its Eligard 7.5mg
one-month product and Eligard 22.5mg three-month product in January
and July 2002, respectively. In April 2002, Atrix submitted a New
Drug Application (NDA) for Eligard 30mg, a four-month sustained
release product, which is currently under FDA review.

Eligard 22.5 mg, like other LHRH agonists, causes a transient
increase in serum concentrations of testosterone during the first
week of treatment. Patients may experience worsening of symptoms or
onset of new signs and symptoms during the first few weeks of
treatment.